Keywords: first, monoclonal, antibody, oked, cancer, usa, developed
First Monoclonal Antibody OKed For Cancer In USA
Article | 31 July 1997
A monoclonal antibody developed by IDEC Pharmaceuticals and Genentech,called Rituxan (rituximab, previously code-named IDEC-C2B8), has been unanimously recommended ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
